Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas

Roger J. Packer, Joanne Ater, Jeffrey Allen, Peter Phillips, Russell Geyer, H. Stacy Nicholson, Regina Jakacki, Elizabeth Kurczynski, Michael Needle, Jonathan Finlay, Gregory Reaman, James M. Boyett

Research output: Contribution to journalArticle

418 Citations (Scopus)

Abstract

The optimum treatment of nonresectable low-grade gliomas of childhood remains undecided. There has been increased interest in the use of chemotherapy for young children, but little information concerning the long- term efficacy of such treatment. Seventy-eight children with a mean age of 3 years (range 3 months- 16 years) who had newly diagnosed, progressive low- grade gliomas were treated with combined carboplatin and vincristine chemotherapy. The patients were followed for a median of 30 months from diagnosis, with 31 patients followed for more than 3 years. Fifty-eight children had diencephalic tumors, 12 had brainstem gliomas, and three had diffuse leptomeningeal gliomas. Forty-four (56%) of 78 patients showed an objective response to treatment. Progression-free survival rates were 75 ± 6% at 2 years and 68 ± 7% at 3 years. There was no statistical difference in progression-free survival rates between children with neurofibromatosis Type 1 and those without the disease (2-year, progression-free survival 79 ± 11% vs. 75 ± 6%, respectively). The histological subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control. The only significant prognostic factor was age: children 5 years old or younger at the time of treatment had a 3-year progression-free survival rate of 74 ± 7% compared with a rate of 39 ± 21% in older children (p <0.01). Treatment with carboplatin and vincristine is effective, especially in younger children in controlling newly diagnosed progressive low-grade gliomas.

Original languageEnglish (US)
Pages (from-to)747-754
Number of pages8
JournalJournal of Neurosurgery
Volume86
Issue number5
StatePublished - May 1997
Externally publishedYes

Fingerprint

Carboplatin
Vincristine
Glioma
Drug Therapy
Disease-Free Survival
Survival Rate
Neurofibromatosis 1
Therapeutics
Brain Stem
Neoplasms

Keywords

  • brainstem tumor
  • chemotherapy
  • chiasmatic glioma
  • children
  • glioma
  • low-grade glioma

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Packer, R. J., Ater, J., Allen, J., Phillips, P., Geyer, R., Nicholson, H. S., ... Boyett, J. M. (1997). Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. Journal of Neurosurgery, 86(5), 747-754.

Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. / Packer, Roger J.; Ater, Joanne; Allen, Jeffrey; Phillips, Peter; Geyer, Russell; Nicholson, H. Stacy; Jakacki, Regina; Kurczynski, Elizabeth; Needle, Michael; Finlay, Jonathan; Reaman, Gregory; Boyett, James M.

In: Journal of Neurosurgery, Vol. 86, No. 5, 05.1997, p. 747-754.

Research output: Contribution to journalArticle

Packer, RJ, Ater, J, Allen, J, Phillips, P, Geyer, R, Nicholson, HS, Jakacki, R, Kurczynski, E, Needle, M, Finlay, J, Reaman, G & Boyett, JM 1997, 'Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas', Journal of Neurosurgery, vol. 86, no. 5, pp. 747-754.
Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. Journal of Neurosurgery. 1997 May;86(5):747-754.
Packer, Roger J. ; Ater, Joanne ; Allen, Jeffrey ; Phillips, Peter ; Geyer, Russell ; Nicholson, H. Stacy ; Jakacki, Regina ; Kurczynski, Elizabeth ; Needle, Michael ; Finlay, Jonathan ; Reaman, Gregory ; Boyett, James M. / Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. In: Journal of Neurosurgery. 1997 ; Vol. 86, No. 5. pp. 747-754.
@article{aab93ac3ae5a4b7385e4aeb70f94047c,
title = "Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas",
abstract = "The optimum treatment of nonresectable low-grade gliomas of childhood remains undecided. There has been increased interest in the use of chemotherapy for young children, but little information concerning the long- term efficacy of such treatment. Seventy-eight children with a mean age of 3 years (range 3 months- 16 years) who had newly diagnosed, progressive low- grade gliomas were treated with combined carboplatin and vincristine chemotherapy. The patients were followed for a median of 30 months from diagnosis, with 31 patients followed for more than 3 years. Fifty-eight children had diencephalic tumors, 12 had brainstem gliomas, and three had diffuse leptomeningeal gliomas. Forty-four (56{\%}) of 78 patients showed an objective response to treatment. Progression-free survival rates were 75 ± 6{\%} at 2 years and 68 ± 7{\%} at 3 years. There was no statistical difference in progression-free survival rates between children with neurofibromatosis Type 1 and those without the disease (2-year, progression-free survival 79 ± 11{\%} vs. 75 ± 6{\%}, respectively). The histological subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control. The only significant prognostic factor was age: children 5 years old or younger at the time of treatment had a 3-year progression-free survival rate of 74 ± 7{\%} compared with a rate of 39 ± 21{\%} in older children (p <0.01). Treatment with carboplatin and vincristine is effective, especially in younger children in controlling newly diagnosed progressive low-grade gliomas.",
keywords = "brainstem tumor, chemotherapy, chiasmatic glioma, children, glioma, low-grade glioma",
author = "Packer, {Roger J.} and Joanne Ater and Jeffrey Allen and Peter Phillips and Russell Geyer and Nicholson, {H. Stacy} and Regina Jakacki and Elizabeth Kurczynski and Michael Needle and Jonathan Finlay and Gregory Reaman and Boyett, {James M.}",
year = "1997",
month = "5",
language = "English (US)",
volume = "86",
pages = "747--754",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "5",

}

TY - JOUR

T1 - Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas

AU - Packer, Roger J.

AU - Ater, Joanne

AU - Allen, Jeffrey

AU - Phillips, Peter

AU - Geyer, Russell

AU - Nicholson, H. Stacy

AU - Jakacki, Regina

AU - Kurczynski, Elizabeth

AU - Needle, Michael

AU - Finlay, Jonathan

AU - Reaman, Gregory

AU - Boyett, James M.

PY - 1997/5

Y1 - 1997/5

N2 - The optimum treatment of nonresectable low-grade gliomas of childhood remains undecided. There has been increased interest in the use of chemotherapy for young children, but little information concerning the long- term efficacy of such treatment. Seventy-eight children with a mean age of 3 years (range 3 months- 16 years) who had newly diagnosed, progressive low- grade gliomas were treated with combined carboplatin and vincristine chemotherapy. The patients were followed for a median of 30 months from diagnosis, with 31 patients followed for more than 3 years. Fifty-eight children had diencephalic tumors, 12 had brainstem gliomas, and three had diffuse leptomeningeal gliomas. Forty-four (56%) of 78 patients showed an objective response to treatment. Progression-free survival rates were 75 ± 6% at 2 years and 68 ± 7% at 3 years. There was no statistical difference in progression-free survival rates between children with neurofibromatosis Type 1 and those without the disease (2-year, progression-free survival 79 ± 11% vs. 75 ± 6%, respectively). The histological subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control. The only significant prognostic factor was age: children 5 years old or younger at the time of treatment had a 3-year progression-free survival rate of 74 ± 7% compared with a rate of 39 ± 21% in older children (p <0.01). Treatment with carboplatin and vincristine is effective, especially in younger children in controlling newly diagnosed progressive low-grade gliomas.

AB - The optimum treatment of nonresectable low-grade gliomas of childhood remains undecided. There has been increased interest in the use of chemotherapy for young children, but little information concerning the long- term efficacy of such treatment. Seventy-eight children with a mean age of 3 years (range 3 months- 16 years) who had newly diagnosed, progressive low- grade gliomas were treated with combined carboplatin and vincristine chemotherapy. The patients were followed for a median of 30 months from diagnosis, with 31 patients followed for more than 3 years. Fifty-eight children had diencephalic tumors, 12 had brainstem gliomas, and three had diffuse leptomeningeal gliomas. Forty-four (56%) of 78 patients showed an objective response to treatment. Progression-free survival rates were 75 ± 6% at 2 years and 68 ± 7% at 3 years. There was no statistical difference in progression-free survival rates between children with neurofibromatosis Type 1 and those without the disease (2-year, progression-free survival 79 ± 11% vs. 75 ± 6%, respectively). The histological subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control. The only significant prognostic factor was age: children 5 years old or younger at the time of treatment had a 3-year progression-free survival rate of 74 ± 7% compared with a rate of 39 ± 21% in older children (p <0.01). Treatment with carboplatin and vincristine is effective, especially in younger children in controlling newly diagnosed progressive low-grade gliomas.

KW - brainstem tumor

KW - chemotherapy

KW - chiasmatic glioma

KW - children

KW - glioma

KW - low-grade glioma

UR - http://www.scopus.com/inward/record.url?scp=0031002713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031002713&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 747

EP - 754

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 5

ER -